Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function.

ABSTRACT:

Background

Oral immunotherapy (OIT) successfully desensitizes patients with food allergies, but the immune mechanisms mediating its efficacy remain obscure.

Objectives

We tested the hypothesis that allergen-specific regulatory T (Treg) cell function is impaired in food allergy and is restored by anti-IgE antibody (omalizumab)-supplemented OIT.

Methods

Peanut-specific T effector (Teff) and Treg cell proliferative responses, activation markers and cytokine expression were analysed by flow cytometry in 13 peanut-allergic subjects before the start of omalizumab-supplemented OIT and periodically in some subjects thereafter for up to 2 years. Peripheral blood regulatory T cells (Treg cells) were analysed for their peanut-specific suppressor function before and at 1 year fol

SUBMITTER: Abdel-Gadir A 

PROVIDER: S-EPMC6021220 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature